Advisor Group Holdings, Inc. Tcr2 Therapeutics Inc. Transaction History

Advisor Group Holdings, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$1.0 - $1.62 $451 - $730	451 Added 33.41%	1,801 $2,000
Q4 2022 Feb 10, 2023	BUY	$0.83 - $1.44 $458 - $794	552 Added 69.17%	1,350 $1,000
Q1 2022 May 04, 2022	SELL	$2.4 - $4.71 $244 - $480	-102 Reduced 11.33%	798 $2,000
Q3 2021 Nov 05, 2021	BUY	$8.44 - $18.35 $4,532 - $9,853	537 Added 147.93%	900 $8,000
Q2 2021 Aug 02, 2021	BUY	$16.41 - $24.71 $5,234 - $7,882	319 Added 725.0%	363 $6,000
Q1 2021 May 13, 2021	BUY	$20.38 - $34.07 $489 - $817	24 Added 120.0%	44 $1,000
Q4 2020 Feb 10, 2021	BUY	$19.0 - $32.63 $380 - $652	20 New	20 $1,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.